MedTrace Logo

Metabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud

NCT07358533 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 176

Last updated 2026-01-23

No results posted yet for this study

Summary

Metabolically Obese Normal Weight (MONW) represents a phenotype affecting individuals with a normal Body Mass Index (BMI) but characterized by excessive adipose tissue accumulation. This condition is associated with increased cardiovascular risk, insulin resistance, and endothelial dysfunction, yet remains underdiagnosed.

This observational longitudinal study aims to comprehensively evaluate the relationship between excessive adipose tissue deposition, endothelial dysfunction, and asprosin concentrations in young women. The study will recruit 176 healthy women aged 18-35 years with normal BMI (\<25 kg/m²). Participants will be divided into two groups based on body fat percentage (PBF) assessed by dual-energy X-ray absorptiometry (DXA): the MONW group (PBF ≥ 35.78%) and the Control group (PBF \< 35.78%).

The specific objectives of the study include:

* Assessment of vascular endothelial function using flow-mediated dilation (FMD) of the brachial artery.
* Evaluation of asprosin as a novel biomarker in the MONW phenotype.
* Analysis of biochemical indices including asymmetric dimethylarginine (ADMA) and von Willebrand factor (vWF).
* Advanced metabolomic profiling to identify metabolic signatures.

Participants will undergo anthropometric measurements, body composition analysis (DXA), and blood sampling for biochemical and hormonal analyses. The study aims to develop predictive models for early cardiovascular risk detection in normal-weight individuals.

Conditions

  • Normal Weight Obesity
  • Metabolically Obese Normal Weight
  • Metabolic Syndrome

Sponsors & Collaborators

  • National Science Centre, Poland

    collaborator OTHER_GOV

  • Pomeranian Medical University Szczecin

    lead OTHER

Principal Investigators

  • Waldemar Pluta, Msc · Pomeranian Medical University in Szczecin

  • Anna Lubkowska, PhD, Prof. · Pomeranian Medical University in Szczecin

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-05-31
Completion
2029-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07358533 on ClinicalTrials.gov